secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001847903-22-000115
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa reports 93% bleed reduction with SerpinPC in 18-month OLE; no safety signals
--------------------------------------------------------------------------------

- Median all-bleeds ABR reduced 93% at 1.2 mg/kg every 2 weeks; median ABR 2.2, 7 of 21 subjects zero bleeds.
- No thromboembolic events or treatment-related D-dimer elevations over 18 months; no SerpinPC-related AEs.
- Pivotal program advancing: PRESent-5 observation study to start in coming weeks; interventional studies planned for 2023.
- Total exposure over 40 patient-years across multiple dosing regimens; sustained safety and tolerability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790322000115/0001847903-22-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790322000115/cnta-20221210.htm
  HTML page:      https://secwatch.observer/filing/0001847903-22-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer